ORIGINAL RESEARCH article
Front. Immunol.
Sec. Alloimmunity and Transplantation
This article is part of the Research TopicMethods in Alloimmunity and Transplantation: 2025View all 13 articles
Anti-Angiotensin II Type 1 Receptor (AT1R) Autoantibodies of IgG3 Subclass Outperform Total Anti-AT1R IgG1-IgG4 Levels in Predicting Transplanted Kidney Antibody-Mediated Rejection
Provisionally accepted
Jakub Mizera1
Karolina Marek-Bukowiec1
Guido Moll2*
Rusan Ali Catar2
Harald Heidecke3
Kai Schulze-Forster3Patryk Jerzak1
Mateusz Rakowski1
Karolina Władyczak1Agnieszka Hałoń1Dariusz Janczak1Piotr Donizy1Mirosław Banasik1- 1Uniwersytet Medyczny im Piastow Slaskich we Wroclawiu, Wrocław, Poland
- 2Charite - Universitatsmedizin Berlin, Berlin, Germany
- 3CellTrend GmbH, Luckenwalde, Germany
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
ABSTRACT Background: Antibody-mediated rejection (AMR) is a leading cause of kidney allograft loss. Anti-angiotensin II type-1 receptor (AT1R) autoantibodies (AABs) have been implicated in AMR and microvascular inflammation (MVI), particularly in C4d-negative and non-HLA antibody dependent cases. Conventional assays measure only total IgG and do not assess pathogenic subclass heterogeneity. Whether IgG1-IgG4 subclass profiling improves AMR prediction has not yet been investigated. Methods: We included 143 adult kidney-transplant recipients who underwent indication biopsy between 2018 and 2025. Histopathology was classified according to Banff 2017–2022 criteria. Serum samples were analysed for total AT1R-IgG (U/mL) and AT1R IgG1–IgG4 subclasses (relative optical density). Associations with AMR were assessed using group comparisons, correlation analysis, logistic regression, ROC AUC, and quartile-based analyses. Results: AT1R-IgG3 levels were significantly elevated in AMR (Kruskal–Wallis, p = 0.0396), correlated with AMR (Spearman ρ = 0.19, p = 0.02), and demonstrated better predictive performance (AUC 0.63 vs 0.53) than total AT1R-IgG. Logistic regression showed stronger associations for IgG3 (OR 1.33, p = 0.0004) than total AT1R-IgG (OR 1.19, p = 0.029). AMR prevalence increased across IgG3 quartiles (Q1:10.5% → Q4:31.6%), while no such trend was observed for total AT1R-IgG. Conclusions: AT1R antibodies of IgG3 subclass outperform total AT1R levels in predicting AMR, revealing pathogenic antibody patterns that are not detectable through global IgG quantitation. Subclass profiling may contribute to more precise AMR risk assessment, but longitudinal and multicentre validation studies with standardized subclass-specific assays are needed to confirm these findings. Although AT1R IgG3 levels were significantly correlated with AMR, the magnitude of these associations is insufficient to support their use as an independent diagnostic marker and may only serve as a complementary AMR marker.
Keywords: anti-angiotensin II type 1 receptor (AT1R), anti-AT1R-directed functional / regulatory autoantibodies (AT1R-AABs/RABs), antibody-mediated rejection (AMR), G protein-coupled receptors (GPCRs), kidney transplantation (KTx), microvascular inflammation (MVI), Non-HLA antibodies
Received: 26 Dec 2025; Accepted: 16 Feb 2026.
Copyright: © 2026 Mizera, Marek-Bukowiec, Moll, Catar, Heidecke, Schulze-Forster, Jerzak, Rakowski, Władyczak, Hałoń, Janczak, Donizy and Banasik. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Guido Moll
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.